

***TNF- α* –308 G>A and –238 G>A polymorphisms are not major risk factors in Caucasian patients with exfoliation glaucoma**

Georg Mossböck,¹ Wilfried Renner,² Yosuf El-Shabrawi,¹ Christoph Faschinger,¹ Otto Schmut,¹ Andreas Wedrich,¹ Christina Zimmermann,¹ Martin Weger¹

¹Department of Ophthalmology, Medical University Graz, Austria; ²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Austria

Purpose: *TNF- α* has been suggested to participate in the pathogenesis of exfoliation glaucoma (XFG). The purpose of the present study was to investigate a hypothesized association between two common functional polymorphisms in the promoter region of the *TNF- α* gene (*TNF- α* –308 G>A, [rs1800629](#), and *TNF- α* –238 G>A, [rs361525](#)) and the presence of XFG in a Caucasian population.

Methods: The present case-control study comprised 408 participants (204 patients with XFG and 204 control subjects). Control subjects were matched for age and sex. Genotypes of the *TNF- α* –308 G>A and *TNF- α* –238 G>A polymorphisms were determined by polymerase chain reaction (restriction fragment length polymorphism).

Results: No significant differences regarding genotype distribution or allelic frequencies were found between patients and control subjects ($p > 0.025$). The presence of the *TNF- α* –308 G-allele was associated with an insignificant odds ratio of 0.98 (95% confidence interval [CI]: 0.66–1.46; $p = 0.99$) while the presence of the *TNF- α* –238 G-allele was associated with an insignificant odds ratio of 0.64 (95% CI: 0.33–1.23; $p = 0.25$).

Conclusions: Our data suggest that both the *TNF- α* –308 G>A and the *TNF- α* –238 G>A polymorphisms are unlikely to be major risk factors for XFG in an European population of Caucasian descent.

Exfoliation syndrome (XFS; OMIM [177650](#)) is recognized as a general elastic fibrillopathy, leading to accumulation of characteristic abnormal fibrillar material in different intra- and extraocular tissues, e.g., trabecular meshwork, iris stroma, conjunctiva, kidney, lung, and heart [1,2]. Glaucomatous optic neuropathy due to XFS (exfoliation glaucoma, XFG) is caused by deposition of exfoliation material and liberated iris pigment in the trabecular meshwork leading to elevation of intraocular pressure [3]. Results from family-based studies and from a study investigating the loss of heterozygosity in specimens of the anterior segment in individuals with XFS indicate a high grade of heritability of XFS [4-8]. Recently, two common non-synonymous single nucleotide polymorphisms (SNPs; [rs1048661](#) and [rs3825942](#)) in the lysyl oxidase-like protein 1 gene (*LOXLI*; OMIM [153456](#)) that confer increased risk for the development of XFS and XFG have been identified [9]. However, as the prevalences of these polymorphisms are also high in individuals without XFS, other, as yet unknown genetic or environmental factors may be involved [10-16].

The degradation of the extracellular matrix (ECM) depends on the activity of a group of highly regulated endopeptidases named matrix metalloproteinases (MMPs), which are grouped in four families consisting of 23 members

in total, each with a specific spectrum of ligands [17]. Uncontrolled activation of MMPs is counterbalanced by specific tissue inhibitors of metalloproteinases (TIMPs), and a delicate balance of MMPs and TIMPs is required for physiologic ECM turnover. Interestingly, increased levels of TIMP-1 and TIMP-2 and decreased levels of MMP-2 have been detected in the aqueous humor of patient with XFS [18, 19]. An impaired balance between MMPs and TIMPs may thus contribute to the development of XFS.

Tumor necrosis factor-alpha (*TNF- α* , OMIM [191160](#)) is a ubiquitous cytokine involved in various physiologic as well as pathologic processes like inflammation, immunoregulation, proliferation, and apoptosis [20]. Notably, several in vitro studies provided evidence that *TNF- α* is also capable of inducing both increased synthesis and activity of MMPs [21-24].

Two common functional polymorphisms in the promoter region of *TNF- α* have been identified. The first is characterized by a G to A substitution at position –308 (*TNF- α* –308 G>A, [rs1800629](#)) while the second is characterized by a G to A substitution at position –238 (*TNF- α* –238 G>A, [rs361525](#)). In vitro studies of these polymorphisms have been shown to increase *TNF- α* production after lipopolysaccharide stimulation [25-27]. Other studies, however, were unable to confirm this effect on *TNF- α* synthesis [27-29].

Only recently, Tekeli and coworkers [30] found an increased prevalence of the *TNF- α* –308 GG genotype among 110 Turkish patients with XFG. This finding, however, has

Correspondence to: Georg Mossböck, MD, Department of Ophthalmology, Medical University Graz, Auenbruggerplatz 4, 8036 Graz, Austria; Phone: +43 316 385 3817; FAX: +43 316 385 3261; email: g.mossboeck@medunigraz.at

not yet been confirmed in other populations, which is mandatory to draw firm conclusions on the role of *TNF- α* polymorphisms. Our study was set to investigate a hypothesized association between the *TNF- α* –308 G>A and *TNF- α* –238 G>A polymorphisms and the presence of XFG.

METHODS

Two hundred and four unrelated patients with XFG and 204 control subjects were enrolled in the present retrospective case-control study. All study participants were Caucasians from the same geographical area in the southern part of Austria. Participants were seen at the Department of Ophthalmology, Medical University Graz (Graz, Austria) between May 2003 and September 2008 and gave informed written consent before enrollment. The study was conducted in accordance with the National Gene Technology Act of Austria and the guidelines of the local ethics committee.

Patients with XFG underwent slit lamp biomicroscopy in mydriasis, testing for best corrected visual acuity, Goldmann applanation tonometry, gonioscopy, pachymetry, and standard automated perimetry (Octopus 101, program G2; Interzeag, Schlieren, Switzerland) or in cases of profoundly decreased visual acuity, Goldmann perimetry. Control subjects underwent slit lamp biomicroscopy in mydriasis, Goldmann applanation tonometry, and testing for best corrected visual acuity. Optic discs in all participants were assessed by glaucoma specialists (C.F., G.M.).

XFG was defined by the presence of typical exfoliation material on the anterior lens capsule, an intraocular pressure before initiation of a pressure lowering therapy of at least 22 mmHg, an open anterior chamber angle, optic disc changes characteristic for glaucoma (notching, thinning of the neuroretinal rim, increased cup/disc ratio in relation to the optic disc size), visual field defects characteristic for glaucoma (inferior or superior arcuate scotoma, nasal step, paracentral scotoma), and absence of conditions leading to secondary glaucoma.

Control subjects showed biomicroscopically no evidence of exfoliation material on the anterior capsule of the lens and no morphological damage indicative for open-angle or angle closure glaucoma. Control subjects were admitted to our department for cataract surgery.

Genotype determination: Venous blood was collected in 5 ml EDTA tubes. DNA was isolated using QIAamp DNA blood mini-kit (QIAGEN, Venlo, Netherlands) and stored at –20 °C. All polymerase chain reactions (PCRs) were run under conditions previously described [31]. Primer sequences for the gene polymorphism at –308 were forward 5'-GGG ACA CAC AAG CAT CAA GG-3' and reverse 5'-GGG ACA CAC AAG CAT CAA GG-3', for the polymorphism at –238 forward 5'-ATC TGG AGG AAG CGG TAG TG-3' and reverse 5'-AGA AGA CCC CCC TCG GAA CC-3'. DNA samples were amplified in 25 μ l aliquots containing 200 μ M

deoxynucleoside triphosphate, 10 μ M of each primer, 1.5 mM MgCl₂, 1 μ l DNA sample, and 2 U Taq polymerase (Applied Biosystems, Foster City, CA). Annealing temperature was 62 °C. The PCR products were digested at 37 °C with NcoI to detect the SNP in the –308 gene allele and MspI to detect the polymorphism of the –238 nucleotide. The PCR product was then subjected to 3% agarose-gel electrophoresis. “No target” controls were included in each PCR batch to ensure that reagents had not been contaminated.

Statistical analysis: Descriptive statistics were used to calculate frequencies and percentages of discrete variables. Continuous data are given as mean \pm standard deviation (SD). Means were compared using the Mann–Whitney test. Proportions of groups were compared by the χ^2 test. The odds ratio (OR) and 95% confidence interval (95% CI) were calculated by logistic regression. According to the Bonferroni correction, the criterion for statistical significance was set at $p \leq 0.025$. Hardy–Weinberg equilibrium has been calculated using HW Diagnostics-Version 1.beta (Fox Chase Cancer Center, Philadelphia, PA). Statistical analysis was done using the SPSS statistical package (version 14.0; SPSS, Chicago, IL).

RESULTS

The present study comprised of 204 patients with XFG (118 female and 86 male) and 204 control subjects, all matched for age and gender. The mean age of patients with XFG was 76.1 \pm 7.0 years (range: 60.6–91.7 years), and the mean age for control subjects was 75.3 \pm 6.9 years (range: 60.3–93.1 years).

The observed genotype distributions did not deviate from those predicted by the Hardy–Weinberg equilibrium, and for control subjects, they were similar to those reported for Caucasian populations [32]. Table 1 shows the genotype and allele frequencies of *TNF- α* –308 G>A and *TNF- α* –238 G>A polymorphisms in patients with XFG and control subjects. No significant differences in either genotype distribution or allelic frequencies of the *TNF- α* –308 G>A and the *TNF- α* –238 G>A polymorphisms were found between patients with XFG and control subjects. The presence of the *TNF- α* –308 G-allele was associated with an insignificant odds ratio of 0.98 (95% CI: 0.66–1.46; $p=0.99$) for XFG. An insignificant odds ratio of 0.64 (95% CI: 0.33–1.23; $p=0.25$) for XFG was also found among carriers of the *TNF- α* –238 G-allele. The present study had a statistical power of 0.80 to detect an odds ratio ≥ 2.09 for the *TNF- α* –308 G/G genotype and an odds ratio ≥ 4.19 for the *TNF- α* –238 G/G genotype in patients with XFG.

DISCUSSION

TNF- α has been shown to affect activity and synthesis of MMPs and TIMPs, which play a major role in the turnover of the ECM in the trabecular meshwork. Treatment of rat cardiac fibroblasts with TNF- α exhibited an increased activity of MMP-2, MMP-9, and MMP-13, while stimulation of human

TABLE 1. DISTRIBUTION OF GENOTYPES AND ALLELIC FREQUENCIES.

<i>TNF-α</i> single nucleotide polymorphism	Patients with XFG (n=204)	Control subjects (n=204)	Significance p-value
<i>TNF-α</i> -308GG	152 (74.5)	151 (74.0)	0.91
-308GA	48 (23.5)	51 (25.0)	0.73
-308AA	4 (2.0)	2 (1.0)	0.41
<i>TNF-α</i> -308 G allele frequency	0.863	0.865	0.92
<i>TNF-α</i> -238GG	182 (89.2)	189 (92.6)	0.23
-238GA	21 (10.3)	15 (7.4)	0.30
-238AA	1 (0.5)	-	-
<i>TNF-α</i> -238 G allele frequency	0.944	0.963	0.18

Distribution of *TNF-α* -308 G>A and *TNF-α* -238 G>A genotypes and allelic frequencies in patients with exfoliation glaucoma and control subjects in an European population of Caucasian descent. Numbers for genotypes are n (%).

smooth muscle cells led to increased activity of MMP-1, MMP-3, and MMP-9 [21,24]. Furthermore, in an in vitro study using human endothelial cells, TNF-α induced increased levels of MMP-14, which in turn activated latent MMP-2 [22]. In mouse osteoblastic cells, mRNA levels of *MMP-3*, *MMP-9*, *TIMP-1*, and *TIMP-3* were upregulated by TNF-α [23].

Various studies provided evidence that MMPs and TIMPs may be involved in the pathogenesis of XFG. Schlötzer-Schrehardt and coworkers found a decreased ratio of MMP-2 to TIMP-2 in the aqueous humor of patients with XFG, which has been corroborated by Määttä and coworkers [18,19]. Ho and coworkers [33] reported significantly increased levels of TIMP-1 in the aqueous humor of patients with XFS, while in an immunohistochemical study Rönkkö and coworkers [34] found decreased ratios of MMPs to TIMPs in trabecular meshwork specimens of patients with XFG. Remarkably, Tekeli and coworkers [30] investigating the common functional *TNF-α* -308 G>A polymorphism suggested that this polymorphism may exert protection against XFG. In their study that included 110 patients with XFG, 6.4% of the patients with XFG were found to have the heterozygote *TNF-α* -308 GA genotype compared to 16.4% of the control subjects. In the present study, no significant differences were found in the genotype distribution or allelic frequency of the *TNF-α* -308 G>A polymorphism as was the case for the *TNF-α* -238 G>A polymorphism. An insignificant odds ratio for XFG was found in both carriers of the *TNF-α* -308 G-allele and of the *TNF-α* -238 G-allele, suggesting that these polymorphisms themselves are not major risk factors for XFG. Possible explanations for these conflicting results may include small sample size as well as varying genotype distributions among different populations.

A limitation of the present study is the sample size, whereby minor genetic effects may be undetected. Furthermore, it can not be ruled out that other, as yet unknown functional polymorphisms in the TNF-α gene influence susceptibility to XFG.

The *TNF-α* -308 G>A polymorphism has also been recently implicated in the pathogenesis of primary open-angle glaucoma. An increased prevalence of the *TNF-α* -308 A-allele was reported in patients with primary open-angle glaucoma in a Chinese study, albeit this result could not be replicated in subsequent studies [35-37].

In conclusion, based on the results of the present study, neither the *TNF-α* -308 G>A nor the *TNF-α* -238 G>A polymorphism is a major risk factor among Caucasian patients with XFG.

ACKNOWLEDGMENTS

The authors thank Ms. Elschatti, Ms. Fischl, Ms. Trummer, and Ms. Wachswender for their skillful technical assistance.

REFERENCES

- Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. *Surv Ophthalmol* 2001; 45:265-315. [PMID: 11166342]
- Schlötzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? *Arch Ophthalmol* 1992; 110:1752-6. [PMID: 1463418]
- Ritch R, Schlötzer-Schrehardt U, Konstas AG. Why is glaucoma associated with exfoliation syndrome? *Prog Retin Eye Res* 2003; 22:253-75. [PMID: 12852486]
- Damji KF, Bains HS, Stefánsson E, Loftsdóttir M, Sverrisson T, Thorgeirsson E, Jonasson F, Gottfredsdóttir M, Allingham RR. Is pseudoexfoliation syndrome inherited? A review of genetic and nongenetic factors and a new observation. *Ophthalmic Genet* 1998; 19:175-85. [PMID: 9895242]
- Orr AC, Robitaille JM, Price PA, Hamilton JR, Falvey DM, De Saint-Sardos AG, Pasternak S, Guernsey DL. Exfoliation syndrome: clinical and genetic features. *Ophthalmic Genet* 2001; 22:171-85. [PMID: 11559859]
- Oliveira C, Schlötzer-Schrehardt U, Vieira G, Liebmann J, Ritch R. Early diagnosis of exfoliation syndrome in the offspring of affected patients. *Acta Ophthalmol Scand* 2006; 84:512-5. [PMID: 16879573]
- Allingham RR, Loftsdóttir M, Gottfredsdóttir MS, Thorgeirsson E, Jonasson F, Sverrisson T, Hodge WG, Damji KF, Stefánsson E. Pseudoexfoliation syndrome in Icelandic

- families. *Br J Ophthalmol* 2001; 85:702-7. [PMID: 11371492]
8. Zalewska R, Pepinski W, Smolenska-Janica D, Mariak Z, Proniewska-Skrettek E, Skawronska M, Janica J. Loss of heterozygosity in patients with pseudoexfoliation syndrome. *Mol Vis* 2003; 9:257-61. [PMID: 12813407]
 9. Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, Stefansson H, Jonsson T, Jonasdottir A, Jonasdottir A, Stefansdottir G, Masson G, Hardarson GA, Petursson H, Arnarsson A, Motallebipour M, Wallerman O, Wadelius C, Gulcher JR, Thorsteinsdottir U, Kong A, Jonasson F, Stefansson K. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. *Science* 2007; 317:1397-400. [PMID: 17690259]
 10. Fingert JH, Alward WL, Kwon YH, Wang K, Streb LM, Sheffield VC, Stone EM. LOXL1 mutations are associated with exfoliation syndrome in patients from the midwestern United States. *Am J Ophthalmol* 2007; 144:974-5. [PMID: 18036875]
 11. Yang X, Zabriskie NA, Hau VS, Chen H, Tong Z, Gibbs D, Farhi P, Katz BJ, Luo L, Pearson E, Goldsmith J, Ma X, Kaminoh Y, Yu B, Zeng J, Zhang K, Yang Z. Genetic association of LOXL1 gene variants and exfoliation glaucoma in a Utah cohort. *Cell Cycle* 2008; 7:521-4. [PMID: 18287813]
 12. Fan BJ, Pasquale L, Grosskreutz CL, Rhee D, Chen T, Deangelis MM, Kim I, Delbono E, Miller JW, Li T, Haines JL, Wiggs JL. DNA sequence variants in the LOXL1 gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity. *BMC Med Genet* 2008; 9:5. [PMID: 18254956]
 13. Hewitt AW, Sharma S, Burdon KP, Wang JJ, Baird PN, Dimasi DP, Mackey DA, Mitchell P, Craig JE. Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. *Hum Mol Genet* 2008; 17:710-6. [PMID: 18037624]
 14. Challa P, Schmidt S, Liu Y, Qin X, Vann R, Gonzalez P, Allingham RR, Hauser MA. Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma. *Mol Vis* 2008; 14:146-9. [PMID: 18334928]
 15. Ramprasad VL, George R, Soumitra N, Sharmila F, Vijaya L, Kumaramanickavel G. Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India. *Mol Vis* 2008; 14:318-22. [PMID: 18334947]
 16. Mossböck G, Renner W, Faschinger C, Schmut O, Wedrich A, Weger M. Lysyl oxidase-like protein 1 (LOXL1) gene polymorphisms and exfoliation glaucoma in a Central European population. *Mol Vis* 2008; 14:857-61. [PMID: 18483563]
 17. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. *J Pathol* 2003; 200:448-64. [PMID: 12845612]
 18. Schlötzer-Schrehardt U, Lommatzsch J, Kühle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2003; 44:1117-25. [PMID: 12601038]
 19. Määttä M, Tervahartala T, Harju M, Airaksinen J, Autio-Harmainen H, Sorsa T. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. *J Glaucoma* 2005; 14:64-9. [PMID: 15650607]
 20. Vassalli P. The pathophysiology of tumor necrosis factors. *Annu Rev Immunol* 1992; 10:411-52. [PMID: 1590993]
 21. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. *Circ Res* 2000; 86:1259-65. [PMID: 10864917]
 22. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, Libby P. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. *J Biol Chem* 1999; 274:11924-9. [PMID: 10207013]
 23. Uchida M, Shima M, Shimoaka T, Fujieda A, Obara K, Suzuki H, Nagai Y, Ikeda T, Yamato H, Kawaguchi H. Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells. *J Cell Physiol* 2000; 185:207-14. [PMID: 11025442]
 24. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. *Circ Res* 1994; 75:181-9. [PMID: 8013077]
 25. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Pena AS. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. *Scand J Immunol* 1996; 43:456-63. [PMID: 8668926]
 26. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. *Clin Exp Immunol* 1998; 113:401-6. [PMID: 9737669]
 27. Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-González A, van Oosten BW, Polman CH, Peña AS. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. *J Neuroimmunol* 1997; 72:149-53. [PMID: 9042107]
 28. Mycko M, Kowalski W, Kwinkowski M, Buenafe AC, Szymanska B, Tronczynska E, Plucienniczak A, Selmaj K. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. *J Neuroimmunol* 1998; 84:198-206. [PMID: 9628463]
 29. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human

- TNF alpha gene promoter. *Scand J Immunol* 1995; 42:501-4. [PMID: 7569785]
30. Tekeli O, Turacli ME, Egin Y, Akar N, Elhan AH. Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma. *Mol Vis* 2008; 14:1815-8. [PMID: 18852869]
 31. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. *Blood* 2001; 97:3707-12. [PMID: 11389006]
 32. Allen RD. Polymorphism of the human TNF-alpha promoter—random variation or functional diversity? *Mol Immunol* 1999; 36:1017-27. [PMID: 10698305]
 33. Ho SL, Dogar GF, Wang J, Crean J, Wu QD, Oliver N, Weitz S, Murray A, Cleary PE, O'Brien C. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. *Br J Ophthalmol* 2005; 89:169-73. [PMID: 15665347]
 34. Rönkkö S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. *Graefes Arch Clin Exp Ophthalmol* 2007; 245:697-704. [PMID: 17028863]
 35. Lin HJ, Tsai FJ, Chen WC, Shi YR, Hsu Y, Tsai SW. Association of tumour necrosis factor alpha -308 gene polymorphism with primary open-angle glaucoma in Chinese. *Eye* 2003; 17:31-4. [PMID: 12579167]
 36. Mossböck G, Weger M, Moray M, Renner W, Haller-Schober EM, Mattes D, Schmut O, Wegscheider B, El-Shabrawi Y. TNF-alpha promoter polymorphisms and primary open-angle glaucoma. *Eye* 2006; 20:1040-3. [PMID: 16138112]
 37. Funayama T, Ishikawa K, Ohtake Y, Tanino T, Kurosaka D, Kimura I, Suzuki K, Ideta H, Nakamoto K, Yasuda N, Fujimaki T, Murakami A, Asaoka R, Hotta Y, Tanihara H, Kanamoto T, Mishima H, Fukuchi T, Abe H, Iwata T, Shimada N, Kudoh J, Shimizu N, Mashima Y. Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma. *Invest Ophthalmol Vis Sci* 2004; 45:4359-67. [PMID: 15557444]